Catalio Capital Management, LP
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), Catalio Capital Management, LP reported 41 stock positions worth $478.7 million. Its top holding was Dianthus Therapeutics (DNTH) at 9.8% of the portfolio, followed by Bridgebio Pharma (BBIO, 6.7%) and Ascendis Pharma A/S (ASND, 6.2%). Compared with Q4 2025, it opened 8 new positions, sold out of 12, added to 13 and reduced 13. The biggest buy was a new position in Definium Therapeutics (DFTX) and the biggest sale an exit from Eli Lilly (LLY).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001958125
- Portfolio Value
- $478.7M (Q1 2026)
- SEC Filing
- 0001958125-26-000003 ↗ filed May 15, 2026
Holdings Value
Holdings 41 stocks · $478.7M
| DNTH Dianthus Therapeutics Inc. | 9.82% | 560,308 | $47.0M | Reduce -14.3% |
| BBIO Bridgebio Pharma Inc. | 6.70% | 432,014 | $32.1M | Add +5.2% |
| ASND Ascendis Pharma A/S | 6.17% | 129,111 | $29.5M | Add +8.3% |
| BMY Bristol-Myers Squibb Co. | 5.33% | 420,727 | $25.5M | Reduce -35.1% |
| SNDX Syndax Pharmaceuticals Inc. | 5.09% | 1,043,670 | $24.4M | Reduce -12.8% |
| GILD Gilead Sciences Inc. | 4.77% | 163,905 | $22.8M | Reduce -43.4% |
| TERN Terns Pharmaceuticals Inc. | 4.50% | 409,031 | $21.6M | Add +198.7% |
| DFTX Definium Therapeutics Inc. | 4.10% | 1,037,984 | $19.6M | New |
| SLNO Soleno Therapeutics Inc. | 4.04% | 577,808 | $19.3M | Add +60.4% |
| BSX Boston Scientific Corp. | 3.92% | 299,318 | $18.8M | Reduce -16.9% |
| RARE Ultragenyx Pharmaceutical Inc. | 3.72% | 850,797 | $17.8M | Add +423.4% |
| INCY Incyte Corp. | 3.58% | 182,101 | $17.1M | New |
| CYTK Cytokinetics Inc. | 2.97% | 215,501 | $14.2M | Reduce -16.6% |
| NTRA Natera Inc. | 2.96% | 70,907 | $14.2M | Add +13.9% |
| CRVS Corvus Pharmaceuticals Inc. | 2.73% | 891,933 | $13.0M | New |
| GPCR Structure Therapeutics Inc. | 2.57% | 255,379 | $12.3M | Add +1.0% |
| MLYS Mineralys Therapeutics Inc. | 2.48% | 439,041 | $11.9M | Add +32.3% |
| EW Edwards Lifesciences Corp. | 2.42% | 144,607 | $11.6M | Reduce -22.7% |
| MANE Veradermics Inc. | 2.29% | 173,582 | $11.0M | New |
| ADPT Adaptive Biotechnologies | 2.10% | 722,784 | $10.0M | Reduce -12.0% |
| HTFL Heartflow Inc. | 2.05% | 403,588 | $9.8M | Add +254.5% |
| KALV Kalvista Pharmaceuticals Inc. | 1.79% | 426,551 | $8.6M | New |
| QURE Uniqure NV | 1.68% | 491,116 | $8.0M | Add +70.3% |
| IRON Disc Medicine Inc. | 1.64% | 122,978 | $7.9M | Add +11.4% |
| SEPN Septerna Inc. | 1.48% | 294,360 | $7.1M | No change |
| ABVX Abivax SA-ADR | 1.10% | 47,193 | $5.3M | Reduce -52.1% |
| DYN Dyne Therapeutics Inc. | 1.07% | 282,954 | $5.1M | Reduce -45.6% |
| ELDN Eledon Pharmaceuticals Inc. | 1.06% | 1,639,816 | $5.1M | Add +30.2% |
| KPTI Karyopharm Therapeutics Inc. | 1.04% | 897,709 | $5.0M | Add +527.8% |
| SUPN Supernus Pharmaceuticals Inc. | 0.67% | 62,019 | $3.2M | Reduce -75.9% |
| TARA Protara Therapeutic Inc. | 0.63% | 580,024 | $3.0M | Reduce -59.9% |
| PHAT Phathom Pharmaceuticals Inc. | 0.57% | 247,767 | $2.8M | Reduce -64.5% |
| NAMS Newamsterdam Pharma Co. NV | 0.56% | 83,554 | $2.7M | New |
| TYRA Tyra Biosciences Inc. | 0.54% | 67,285 | $2.6M | New |
| IMCR Immunocore Holdings PLC-ADR | 0.53% | 84,352 | $2.5M | New |
| GUTS Fractyl Health Inc. | 0.53% | 5,491,866 | $2.5M | No change |
| HYPR Hyperfine Inc. | 0.30% | 1,320,041 | $1.4M | No change |
| MGX Metagenomi Therapeutics Inc. | 0.15% | 528,993 | $709K | No change |
| ATAI Ataibeckley Inc. | 0.15% | 196,858 | $697K | No change |
| FTH Faeth Therapeutics Inc. filed as SENSEI BIOTHERAPEUTICS INC | 0.10% | 14,718 | $464K | No change |
| OM Outset Medical Inc. | 0.09% | 118,279 | $454K | No change |
Portfolio Sells Q4 2025 → Q1 2026
| LLY Eli Lilly & Co. | Sold out | 0.00% | −4.92 |
| JNJ Johnson & Johnson | Sold out | 0.00% | −4.42 |
| REGN Regeneron Pharmaceuticals | Sold out | 0.00% | −4.07 |
| ISRG Intuitive Surgical Inc. | Sold out | 0.00% | −2.72 |
| BSX Boston Scientific Corp. | Reduce -16.9% | 3.92% | −2.15 |
| ADMA Adma Biologics Inc. | Sold out | 0.00% | −1.82 |
| ACLX Arcellx Inc. | Sold out | 0.00% | −1.80 |
| SUPN Supernus Pharmaceuticals Inc. | Reduce -75.9% | 0.67% | −1.59 |
| OCUL Ocular Therapeutix Inc. | Sold out | 0.00% | −1.53 |
| GILD Gilead Sciences Inc. | Reduce -43.4% | 4.77% | −1.50 |
| PHAT Phathom Pharmaceuticals Inc. | Reduce -64.5% | 0.57% | −1.47 |
| ABVX Abivax SA-ADR | Reduce -52.1% | 1.10% | −1.25 |
| OLMA Olema Pharmaceuticals Inc. | Sold out | 0.00% | −1.18 |
| BMY Bristol-Myers Squibb Co. | Reduce -35.1% | 5.33% | −0.85 |
| TARA Protara Therapeutic Inc. | Reduce -59.9% | 0.63% | −0.73 |
| DYN Dyne Therapeutics Inc. | Reduce -45.6% | 1.07% | −0.73 |
| GRAL Grail Inc. | Sold out | 0.00% | −0.46 |
| FULC Fulcrum Therapeutics Inc. | Sold out | 0.00% | −0.40 |
| EW Edwards Lifesciences Corp. | Reduce -22.7% | 2.42% | −0.40 |
| BLLN Billiontoone Inc. Class A | Sold out | 0.00% | −0.37 |
| ADPT Adaptive Biotechnologies | Reduce -12.0% | 2.10% | −0.26 |
| PVLA Palvella Therapeutics Inc. | Sold out | 0.00% | −0.19 |
| CYTK Cytokinetics Inc. | Reduce -16.6% | 2.97% | +0.07 |
| SNDX Syndax Pharmaceuticals Inc. | Reduce -12.8% | 5.09% | +0.65 |
| DNTH Dianthus Therapeutics Inc. | Reduce -14.3% | 9.82% | +5.06 |
Portfolio Buys Q4 2025 → Q1 2026
| DFTX Definium Therapeutics Inc. | New | 4.10% | +4.10 |
| INCY Incyte Corp. | New | 3.58% | +3.58 |
| TERN Terns Pharmaceuticals Inc. | Add +198.7% | 4.50% | +3.53 |
| RARE Ultragenyx Pharmaceutical Inc. | Add +423.4% | 3.72% | +3.06 |
| CRVS Corvus Pharmaceuticals Inc. | New | 2.73% | +2.73 |
| MANE Veradermics Inc. | New | 2.29% | +2.29 |
| KALV Kalvista Pharmaceuticals Inc. | New | 1.79% | +1.79 |
| ASND Ascendis Pharma A/S | Add +8.3% | 6.17% | +1.67 |
| HTFL Heartflow Inc. | Add +254.5% | 2.05% | +1.46 |
| BBIO Bridgebio Pharma Inc. | Add +5.2% | 6.70% | +1.15 |
| SLNO Soleno Therapeutics Inc. | Add +60.4% | 4.04% | +1.09 |
| KPTI Karyopharm Therapeutics Inc. | Add +527.8% | 1.04% | +0.86 |
| ELDN Eledon Pharmaceuticals Inc. | Add +30.2% | 1.06% | +0.72 |
| NAMS Newamsterdam Pharma Co. NV | New | 0.56% | +0.56 |
| TYRA Tyra Biosciences Inc. | New | 0.54% | +0.54 |
| IMCR Immunocore Holdings PLC-ADR | New | 0.53% | +0.53 |
| QURE Uniqure NV | Add +70.3% | 1.68% | +0.46 |
| NTRA Natera Inc. | Add +13.9% | 2.96% | +0.44 |
| MLYS Mineralys Therapeutics Inc. | Add +32.3% | 2.48% | +0.36 |
| IRON Disc Medicine Inc. | Add +11.4% | 1.64% | +0.09 |
| GPCR Structure Therapeutics Inc. | Add +1.0% | 2.57% | −0.54 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 39 | $532.1M | AVLN, JNJ, GILD, BBIO, SNDX |
| Q1 2026 | 41 | $478.7M | DNTH, BBIO, ASND, BMY, SNDX |
| Q4 2025Amended | 45 | $565.8M | GILD, BMY, BSX, BBIO, LLY |
| Q3 2025 | 38 | $540.9M | LLY, ABBV, BBIO, ISRG, ASND |
| Q2 2025 | 40 | $476.9M | LLY, BBIO, SLNO, ASND, ISRG |
| Q1 2025 | 35 | $403.4M | BDX, SWTX, BBIO, EW, ASND |
| Q4 2024 | 33 | $457.1M | BDX, ASND, BMY, SWTX, BPMC |